FDA approval of Geron’s Embryonic Stem Cell Trial Has Widespread Implications For Rare Disease

In its Friday press release, Geron, the California-based biotech, announced the FDA’s clearance to proceed with its embryonic stem cell trial for spinal cord injury. This will be the first clinical trial to test the use of embryonic stem cells in human patients, and it will have widespread implications for many other common and rare diseases, including Canavan disease.